2,2,6,6-Tetramethylpiperidin-1-oxyl
Fernando Montanari(University of Milan), Yu Zong(The Barbara Ann Karmanos Cancer Institute), Huda Henry‐Riyad(University of Toronto), Silvio Quici(University of Milan), Armido Studer(University of Münster), Chao Zhang(University of Science and Technology Beijing), Thomas Vogler(University of Münster), Yu Rao(Soochow University), Thomas T. Tidwell(University of Toronto)
Cited by 2
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270